GlassScriptPhysician profile
William Charles Howland
NPI 1770550535
$8,467.27
in general payments reported to CMS, 2019-2025
26 companies · $1,724 in 2025
The $1,724 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,975 · 2020: $590 · 2021: $720 · 2022: $458 · 2025: $1,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,186 · Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,185.54 |
| Food and Beverage | $538.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,904.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,587.42 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,114.34 | 2019-2022 | |
| Genzyme Corporation | $573.27 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $402.26 | 2019-2021 | |
| Amgen INC. | $194.62 | 2022 | |
| Galderma Laboratories, L.P. | $136.40 | 2025 | Nemluvio |
| Abbvie INC. | $125.54 | 2022 | |
| Glaxosmithkline, LLC. | $95.86 | 2019-2020 | |
| Alk-Abello, INC | $95.61 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.86 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.54 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $43.59 | 2020-2021 | |
| Mylan Specialty L.P. | $23.55 | 2020 | |
| Kaleo, INC. | $19.92 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $16.82 | 2020 | |
| Genentech USA, INC. | $16.66 | 2019 | |
| Circassia INC. | $15.27 | 2019 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Howland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.